What is the level of liabilities of Biontech this year?
Biontech has a debt balance of 2.76 B EUR this year.
Biontech Liabilities 2024
Biontech Liabilities
2.76 B EUR
Ticker
BNTX
ISIN
US09075V1026
WKN
A2PSR2
In 2024, Biontech's total liabilities amounted to 2.76 B EUR, a -14.38% difference from the 3.22 B EUR total liabilities in the previous year.
Biontech Aktienanalyse
What does Biontech do?
BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Biontech's Liabilities
Biontech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Biontech's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Biontech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Biontech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Biontech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Biontech stock
What were the liabilities of Biontech compared to the previous year?
The liabilities of Biontech have increased by -14.38% dropped compared to the previous year.
What are the consequences of high debt for investors of Biontech?
High liabilities can pose a risk for investors of Biontech, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Biontech?
Low liabilities mean that Biontech has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Biontech affect the company?
An increase in liabilities of Biontech can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Biontech affect the company?
A decrease in the liabilities of Biontech can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Biontech?
Some factors that can influence the liabilities of Biontech include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Biontech so important for investors?
The liabilities of Biontech are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Biontech take to modify the liabilities?
To change its liabilities, Biontech can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Biontech pay?
Over the past 12 months, Biontech paid a dividend of 2.13 EUR . This corresponds to a dividend yield of about 2.07 %. For the coming 12 months, Biontech is expected to pay a dividend of 0 EUR.
What is the dividend yield of Biontech?
The current dividend yield of Biontech is 2.07 %.
When does Biontech pay dividends?
Biontech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biontech?
Biontech paid dividends every year for the past 2 years.
What is the dividend of Biontech?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biontech located?
Biontech is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biontech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biontech from 6/17/2022 amounting to 2.132 EUR, you needed to have the stock in your portfolio before the ex-date on 6/2/2022.
When did Biontech pay the last dividend?
The last dividend was paid out on 6/17/2022.
What was the dividend of Biontech in the year 2023?
In the year 2023, Biontech distributed 2.132 EUR as dividends.
In which currency does Biontech pay out the dividend?
The dividends of Biontech are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Biontech stock can be added to a savings plan with the following providers: Scalable Capital and Consorsbank
Andere Kennzahlen von Biontech
Our stock analysis for Biontech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biontech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
